Thera-SAbDab

BEDINVETMAB

>   Structural Summary
TherapeuticBedinvetmab
TargetCanine NGFB
Heavy ChainEVQLVESGGDLVKPGGSLRLSCVASGFTFSSHGMHWVRQSPGKGLQWVAVINSGGSSTYYTDAVKGRFTISRDNAKNTVYLQMNSLRAEDTAMYYCAKESVGGWEQLVGPHFDYWGQGTLVIVSS
Light ChainQSVLTQPTSVSGSLGWRVTISCSGSTNNIGILGASWYQLFPGKAPKLLVYGNGNRPSGVPDRFSGADSGDSVTLTITGLQAEDEADYYCQSFDTTLGAHVFGGGTHLTVL
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatCanine Whole mAb
IsotypeG2
Highest Clinical Trial (June '19)Unknown
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2018
INN Year Recommended2019
Companies Involvedna
Conditions Approvedna
Conditions ActiveCanine lupus familiaris
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]